User Name  Password
Title: April 2008 Chantix Safety Warnings
  • AskJoel
  •        Chantix
Hop to: 
New Topic New Poll
<<Previous ThreadNext Thread>>
Page 1 / 1    

From: USA
Registered: 11/14/2008

(Date Posted:11/17/2008 12:56 PM)
Share to: Facebook Twitter MSN linkedin google yahoo

From: John (Gold)  (Original Message)Sent: 4/1/2008 11:24 AM

New Safety Warnings about Chantix(Video, print, and e-mail functions)

FDA is alerting healthcare professionals about new safety warnings for Chantix (varenicline), a drug used to help people stop smoking. 

Chantix has been linked to serious neuropsychiatric problems, including changes in behavior, agitation, depressed mood, suicidal ideation and suicide. The drug can cause an existing psychiatric illness to worsen, or an old psychiatric illness to recur. The symptoms can occur even after the drug is discontinued. 

People who are trying to give up smoking often experience mood swings, irritability and other changes in behavior. But as the reports accumulate, it becomes clearer that there is a link with the drug. For example, some of the patients who experienced these psychiatric symptoms hadn't actually quit smoking.

Physicians and patients have to make an informed decision about whether Chantix is suitable, but in order to do that, it's important that they exchange some important information. For example, physicians should inquire about past psychiatric illnesses before they prescribe Chantix, and patients should be educated to volunteer this information. The premarketing studies of Chantix did not include patients with serious psychiatric illnesses, so the safety of Chantix in these patients hasn't been established. 

It is also important for everyone involved in the patient's care (including family members and caregivers) to be vigilant about changes in mood and behavior during the treatment. Things to watch out for include anxiety, nervousness, depressed mood, vivid or unusual dreams, and thinking about or attempting suicide. These changes should be immediately reported to the physician.

Patients should also know that the drug can impair their ability to drive or operate heavy machinery.

To help educate patients about all of these issues, FDA is working with Pfizer, the manufacturer of Chantix, to develop a Medication Guide that will be dispensed with each prescription.

Additional Information:

FDA MedWatch Safety Alert. Varenicline (marketed as Chantix). February 1, 2008.

FDA Press Release. FDA Issues Public Health Advisory on Chantix. February 1, 2008.

Recommend Message 20 of 21 in Discussion 
From: JoelSent: 4/3/2008 4:27 PM

FDA pulls video clip
admitting Chantix suicide link

Click this link to watch a 4/1/08 FDA video clip discussing Chantix risk factorsOn Tuesday FDA Patient Safety News released a video clip sharing safety warnings about "serious neuropsychiatric problems" in users of Pfizer's quit smoking pill Chantix, including suicide. Featured yesterday in a WhyQuit article exploring concerns raised by the video, this morning FDA site links to the clip were no longer functional.

The FDA has yet to respond to inquiry as to why the video clip was pulled and whether or not Pfizer played any role in the FDA's decision to do so.

A copy of the pulled FDA Chantix clip is being made available for viewing at WhyQuit. WhyQuit shares this clip based upon the FDA's Patient Safety News website assertion that, "FDA Patient Safety News is a product of the US Federal Government, and as such is NOT copyrighted or restricted in any way. We encourage the further use and distribution of the video or text of the program by anyone – either in its entirety or as individual stories."

In a separate development, it's reported that Public Citizen, a non-profit Washington based consumer protection watchdog, has called upon the FDA to require a "black box" warning label for Chantix due to suicide and other behavioral risk factors. Reserved for drugs linked to serious or life-threatening adverse events, a "black box" warning is the strongest warning the FDA can mandate.


Recommend Message 21 of 21 in Discussion 
From: JoelSent: 5/21/2008 5:50 PM
| and 7mb audio only format, length 48 minutes, recorded 10/19/07 by Joel Spitzer
  • Flawed research equates placebo to cold turkey - John R. Polito, 03/07
  • Nicotine Fix - Behind Antismoking Policy, Influence of Drug Industry - Kevin Helliker, 02/07
  • Evidence of Collusion: Pharma-Govt Smoking Guidelines - AHRP, 02/07
  • WSJ Highlights Financial Conflicts of Chair of Federal Guidelines Panel - Michael Siegel, MD 02/07
  • Nixing the Patch: Smokers quit cold turkey - Ken Millstone, 02/07
  • New Study Challenges Thinking on Use of NRT During Pregnancy - Michael Siegel, MD, 02/07
  • Nicotine for the Fetus, the Infant and Adolescent - H.K. Ginzel, MD, 02/07
  • The secret to quitting smoking - John R. Polito, 01/07
  • Financial Ties Between Guideline Panels and Big Pharma Run Deep - Michael Siegel, MD, 01/07
  • Chantix - an 8 in 10 failure rate or worse? - John R. Polito, 12/06
  • Do physician's have a legal duty to ignore Guideline Recommendation 7? - John R. Polito, 12/06
  • Chantix likely as ineffective as NRT - John R. Polito, 11/06
  • Is the U.S. government's quitting policy killing smokers? - John R. Polito, 10/06
  • Will Chantix really help me quit smoking? - John R. Polito, 08/06
  • It's unlikely this NRT study was blind - John R. Polito, 08/06
  • Conference Sponsorship by Pharma Precludes Objective Symposium - Michael Siegel, MD 07/06
  • 13th World Conference on Tobacco or Health Drenched in Nicotine - John R. Polito, 07/06
  • Cold Turkey Twice as Effective as NRT or Zyban - John R. Polito, 05/06
  • Nicotine Not Medicine, Its Use Not Therapy - John R. Polito, 04/06
  • How to use behavorial findings to sell NRT - John R. Polito, 01/06
  • GlaxoSmithKline Attacks Cold Turkey Quitting - John R. Polito, 12/05
  • UK Guidance for NRT use in pregnancy and by children - ASH London, 12/05
  • June 2000 Guideline Chairman Michael Fiore's Testimony - see PDF pages 14 & 15, 05/05
  • The Nicotine Patch, Gum and Lozenge - Mounting Evidence of a Sham - John R. Polito, 04/05
  • 40 Years of Progress? - Joel Spitzer, 10/04
  • Widespread Blinding Failures Put NRT Studies in Serious Question - John R. Polito, 06/04
  • Nicotine Gum Maker's Concern Raises Concerns - John R. Polito, 05/04
  • A Quitter's Dilemma: Hooked on the Cure - New York Times, 05/04
  • Quebec CT Quitters Disprove "Double Your Chances" NRT Assertion - John R. Polito, 04/04
  • Are nicotine weaning products a bad joke? - John R. Polito, 10/03
  • Is CT Quitting More Productive & Effective than NRT? - John R. Polito, 07/03
  • Are Teens Getting Hooked on NRT? - John R. Polito, 06/03
  • March 2003 OTC NRT Meta-Analysis Finds 93% Midyear Relapse Rate - John R. Polito, 03/03
  • Quitting Methods - Who to Believe? - Joel Spitzer, 2003
  • JAMA Study Concludes NRT is Ineffective - John R. Polito, 09/02
  • Real-World Nicotine Patch and Gum Rates - John R. Polito, 06/02
  • Does the OTC Nicotine Patch Really Double Your Chances of Quitting? - John R. Polito, 04/02
  • Is Nicotine Replacement Therapy The Smoker's Last Best Hope? - John R. Polito, 11/00
  • Financial Disclosures for June 2000 Guideline Panel - U.S. Public Health Service, 06/00
  • June 2000 Guideline Recommendation 7 - pharmacotherapy use by all quitters - 06/00

  • WhyQuit.Com   |  Joel's Library  |  About Us  |  Contact Us  |  Link to Us  |  What's New?

    Chantix blamed for 3,063
    serious injuries and 78 deaths

    May 21, 2008

    study released today examined 6,363 U.S. Food and Drug Administration (FDA) adverse drug reaction reports implicating Pfizer's quit smoking pill Chantix (varenicline) and found that 3,063 involved serious injuries. Its recommendation? "We recommend that patients and doctors exercise caution in the use of varenicline and consider the use of alternative approaches to smoking cessation."

    Authored by The Institute for Safe Medication Practices (ISMP), a non-profit medication watchdog, ISMP looks for safety flags while monitoring all adverse events reported to the FDA for all medications.

    ISMP monitoring noted that "by the 3rd quarter of 2007 varenicline produced a signal not previously seen for any other drug. It produced more serious reports than any other drug for multiple types of events: more potential cases of angioedema, cardiac arrhythmia, diabetes and severe cutaneous injury. By the 4th quarter of 2007 varenicline accounted for more reports of serious drug adverse events in the United States than any other drug."

    During the 4th quarter of 2007 the FDA received 998 reports of serious varenicline adverse events compared to only 372 for the addictive troublemaker oxycodone, a potent medication for relief of moderate to severe pain. While ISMP estimates that a total of 3.5 million Chantix (varenicline) prescriptions were written in the U.S. since FDA approval in May 2006, government estimates place annual oxycodone prescriptions written at more than 7 million.

    The study found that while the FDA has issued warnings regarding Chantix's link to suicidal acts, thoughts or behaviors, psychosis, hostility and aggression, it has ignored "other kinds of serious harm for which no warnings now exist, either from the FDA or from the manufacturer, Pfizer Inc."

    While the FDA received 78 death reports in which "varenicline was the principal suspect drug," only 28 resulted from suicide. There were "numerous reports suggesting cardiac causes, both thromboembolic and arrhythmic," writes ISMP.

    Among reports of serious events were 173 accidents and injuries, 338 angioedemas, 224 cardiac arrhythmias, 86 convulsions, 139 embolic and thrombotic events, 372 extrapyramidal syndromes, 544 cases of hyperglycemia/new onset diabetes mellitus, 525 reports of hostility/aggression, 397 psychosis and psychotic disorders, 227 reports of suicide/self-injury, 65 severe cutaneous adverse reactions, and 148 vision disturbances.

    Could there possibly be a common thread among such a diverse group of disorders? Yes, says the ISMP study. A subtype of acetylcholine receptor known as alpha 4 beta 2 plays "numerous roles in the brain and body and is central to muscle contractions -- both voluntary movement and heart muscle contractions, as well as the tone of the smooth muscles that line the blood vessels."

    According to the study, Pfizer researchers found that varenicline was most active against alpha 4 beta 2 type acetylcholine receptors. They focused on the fact that it caused the release of dopamine within the brain while blocking nicotine from occupying alpha 4 beta 2 receptors. It notes that "many antipsychotic drugs block dopamine receptors, but they also cause movement disorders. The loss of muscle control seen in Parkinson's disease is the result of the destruction of dopamine-producing cells in the brain."

    The gravity and number of serious injuries attributed to Chantix caused the report to lightly touch on an equally pressing risk analysis concern, the value of Chantix in helping smokers quit. While noting that counseling rich varenicline clinical trials produced 52-week quit rates of approximately 22 percent, it cites two early nicotine gum studies while noting that they achieved comparable rates.

    In fact, a 1976 nicotine gum study headed by Russell found that 23% of nicotine gum users were still not smoking at 1 year. The 1980 nicotine gum study by Raw produced a whopping 38% rate, in 1982 Jarvis found a 31% rate, in 1983 Schneider 30%, in 1984 Hialmarson 29%, in 1986 Daughton 31%, in 1987 Kornitzer 32%, and in 1989 Tonnesen boasted a 44% one year quit smoking rate.

    What wasn't mentioned in the ISMP study was that in real-world competition, outside of clinical trials that were rich in support and counseling, nearly all quitting method surveys to date show that, long-term, cold turkey quitters actually perform better than users of nicotine gum, patch, lozenge and Zyban.

    A 2006 National Cancer Institute quitting method survey of 8,200 smokers found that at 9 months 16% of "on your own" quitters were still not smoking compared to just 14% among quitters relying upon the nicotine patch, gum, lozenge or Zyban.

    While ISMP faults the FDA for neglect in warning Chantix users about risks other than mental and emotional, just as culpable is its approval of Pfizer's clinical trial design when: (1) they involved a record number of provider counseling/support contacts (twenty-five), contacts the FDA knows could account for nearly all effectiveness seen; (2) no assessments to test study blinding was requested or conducted, when the FDA knows that it is probably impossible to blind drug addiction studies, as smokers with any quitting history recognize the onset of full-blown nicotine withdrawal; (3) excluded 28% of study applicants, including nearly all having any significant medical condition, and then permitted Pfizer to market Chantix to groups intentionally excluded; and (4) allowed NRT use between the end of treatment and week 52, and then certified ongoing NRT users as having been successful Chantix quitters.

    If Pfizer knows, via real-world quitting data gathered through its website, that Chantix's real-world effectiveness is substantially less than shown in clinical trials, with Chantix injuries so numerous and serious, does Pfizer have both legal and ethical duties to immediately share that data with both the FDA and smokers considering using Chantix?

    If Chantix isn't living up to Pfizer marketing hype, do reports like this ISMP study obligate Pfizer to be more forthright, honest and clear about both varenicline's safety and effectiveness?

    "These data provide a strong signal that the risks of varenicline treatment have been underestimated, and show that a wide spectrum of serious injuries are being reported in large numbers," ISMP warns.

    "Table 1 shows that in the 4th quarter of 2007, the other highest ranked drugs (e.g. fentanyl, interferon beta, etanercept) are all high alert drugs with black box warnings, are intended for serious illness in patients and have benefits that are accompanied by substantial risks. In comparison, varenicline is intended for use in healthy people to help stop smoking."

    Does it make sense, if inside a very slow burning building, to pay money for the right to use the most dangerous exist path out?

    Never in the history of smoking cessation has any quitting product harmed so many. It makes one wonder whether instead of helping smokers the FDA and Pfizer have declared war upon them.


    No Copyright - This Article is Public Domain

    John R. Polito is solely responsible for the content of this article.
    Any factual error will be immediately corrected upon receipt of credible authority 
    in support of the writer's contention. E-mail comments to

    Related Links and Articles

    Knowledge is Power!

    Knowledge is a Quitting Method!

    WhyQuit.Com   |  Joel's Library  |  About Us  |  Contact Us  |  Link to Us  |  What's New?
    <<Previous ThreadNext Thread>>
    Page 1 / 1    
    New Topic New Poll
    Sign Up | Create | About Us | SiteMap | Features | Forums | Show Off | Faq | Help
    Copyright © 2000-2019 Aimoo Free Forum All rights reserved.

    Get cheapest China Wholesale,  China Wholesale Supplier,  SilkChain 丝链to be a retailer is easy now.